Facility closures are among the most operationally intense events a biotech or pharmaceutical company can face. Alongside HR, IT, and lease obligations, the physical asset footprint — lab instruments, process equipment, furniture, and infrastructure — must be systematically managed on a compressed timeline. Poor planning in this phase routinely costs companies hundreds of thousands of dollars in lost recovery value, lease overruns, and remediation expenses.
Phase 1: Asset Inventory and Triage (Weeks 1–3)
The first step in any facility closure disposition is a comprehensive asset inventory. This means physically walking every space — labs, storage rooms, mechanical rooms, server rooms — and cataloging everything with make, model, serial number, condition, and estimated replacement value.
Once inventoried, assets fall into four categories: (1) transferred to another facility or entity, (2) sold via direct sale or auction, (3) donated or recycled, (4) disposed as waste. Getting this triage right early determines which disposition channels you'll activate and in what sequence.
For leased equipment, verify which assets are owned versus leased. Leased items must be coordinated with the lessor — attempting to sell leased equipment is a common and costly mistake.
Phase 2: Compliance Clearances
Biotech and pharma facilities often house regulated materials and equipment that require clearance before disposition. This includes biohazard decontamination, radioactive material handling (for any equipment with licensed radiation sources), hazmat characterization of chemical-contaminated equipment, and DEA permit requirements for controlled substance-handling instruments.
Equipment sold without proper decontamination certification will either be rejected by buyers or expose your organization to regulatory liability. Budget time and cost for professional decontamination and obtain documentation — buyers of ex-pharma equipment expect this and will ask for it.
Note: pForm Asset Solutions coordinates logistics and disposition management but does not perform decontamination or regulatory compliance activities. We work alongside your EHS team or licensed remediation contractors to ensure equipment is cleared before transfer.
Phase 3: Disposition Execution
With inventory and compliance complete, disposition execution follows a tiered priority approach. High-value instruments identified in triage go to market first — either through targeted outreach to qualified buyers in your network or through an invitation-only preview before public auction. Early access to motivated buyers captures the best pricing.
Mid-value equipment is packaged into curated lots for online auction. Grouping complementary equipment (e.g., a complete cell culture suite: biosafety cabinets, CO2 incubators, centrifuges, microscopes) attracts buyers who want to set up operational labs quickly and are willing to pay a premium for cohesive lots.
Lower-value laboratory consumables, glassware, and furniture are typically handled through bulk lot sale or direct recycling partnerships. The cost of individually cataloging and auctioning a $40 graduated cylinder is never justified.
Phase 4: Removal and Facility Return
Asset removal must be coordinated with your landlord's access requirements and your lease termination date. Most commercial lab leases require the tenant to return the space in broom-clean condition, which means all equipment removed and any penetrations or anchor points patched.
Schedule removal in reverse order of access complexity — roof-mounted HVAC and mechanical equipment last, benchtop instruments first. For large equipment (autoclaves, freezer farms, fume hood arrays), engage riggers early; rigging equipment is frequently in high demand and scheduling can be a bottleneck.
Maintain a detailed removal log with photos of each space before and after removal. This documentation protects you in any landlord disputes over condition at turnover.
A well-executed biotech facility closure disposition protects capital, meets lease obligations on time, and keeps the organization out of regulatory trouble. The difference between a managed process and a scrambled one can easily be $500,000 or more in net outcome on a mid-size facility. Engaging an experienced disposition partner early — before the timeline compresses — is the highest-leverage decision you can make.